Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Lack of RAC.

Calos MP.

Mol Ther. 2018 Oct 3;26(10):2327. doi: 10.1016/j.ymthe.2018.09.007. Epub 2018 Sep 20. No abstract available.

2.

DNA-Mediated Gene Therapy in a Mouse Model of Limb Girdle Muscular Dystrophy 2B.

Ma J, Pichavant C, du Bois H, Bhakta M, Calos MP.

Mol Ther Methods Clin Dev. 2017 Oct 24;7:123-131. doi: 10.1016/j.omtm.2017.10.005. eCollection 2017 Dec 15.

3.

Use of the DICE (Dual Integrase Cassette Exchange) System.

Farruggio AP, Bhakta MS, Calos MP.

Methods Mol Biol. 2017;1642:69-85. doi: 10.1007/978-1-4939-7169-5_5.

PMID:
28815494
4.

Genome Editing Techniques and Their Therapeutic Applications.

Calos MP.

Clin Pharmacol Ther. 2017 Jan;101(1):42-51. doi: 10.1002/cpt.542. Epub 2016 Nov 18. Review.

PMID:
27783398
5.

The CRISPR Way to Think about Duchenne's.

Calos MP.

N Engl J Med. 2016 Apr 28;374(17):1684-6. doi: 10.1056/NEJMcibr1601383. No abstract available.

PMID:
27119241
6.

Precise Correction of Disease Mutations in Induced Pluripotent Stem Cells Derived From Patients With Limb Girdle Muscular Dystrophy.

Turan S, Farruggio AP, Srifa W, Day JW, Calos MP.

Mol Ther. 2016 Apr;24(4):685-96. doi: 10.1038/mt.2016.40. Epub 2016 Feb 26.

7.

In vivo blunt-end cloning through CRISPR/Cas9-facilitated non-homologous end-joining.

Geisinger JM, Turan S, Hernandez S, Spector LP, Calos MP.

Nucleic Acids Res. 2016 May 5;44(8):e76. doi: 10.1093/nar/gkv1542. Epub 2016 Jan 13.

8.

Using phage integrases in a site-specific dual integrase cassette exchange strategy.

Geisinger JM, Calos MP.

Methods Mol Biol. 2015;1239:29-38. doi: 10.1007/978-1-4939-1862-1_3.

PMID:
25408400
9.

Serine integrase chimeras with activity in E. coli and HeLa cells.

Farruggio AP, Calos MP.

Biol Open. 2014 Sep 12;3(10):895-903. doi: 10.1242/bio.20148748.

10.

Recombinase-mediated reprogramming and dystrophin gene addition in mdx mouse induced pluripotent stem cells.

Zhao C, Farruggio AP, Bjornson CR, Chavez CL, Geisinger JM, Neal TL, Karow M, Calos MP.

PLoS One. 2014 Apr 29;9(4):e96279. doi: 10.1371/journal.pone.0096279. eCollection 2014.

11.

DICE, an efficient system for iterative genomic editing in human pluripotent stem cells.

Zhu F, Gamboa M, Farruggio AP, Hippenmeyer S, Tasic B, Schüle B, Chen-Tsai Y, Calos MP.

Nucleic Acids Res. 2014 Mar;42(5):e34. doi: 10.1093/nar/gkt1290. Epub 2013 Dec 4.

12.

Safe genetic modification of cardiac stem cells using a site-specific integration technique.

Lan F, Liu J, Narsinh KH, Hu S, Han L, Lee AS, Karow M, Nguyen PK, Nag D, Calos MP, Robbins RC, Wu JC.

Circulation. 2012 Sep 11;126(11 Suppl 1):S20-8.

13.

Efficient reversal of phiC31 integrase recombination in mammalian cells.

Farruggio AP, Chavez CL, Mikell CL, Calos MP.

Biotechnol J. 2012 Nov;7(11):1332-6. doi: 10.1002/biot.201200283. Epub 2012 Oct 10.

14.

Site-specific integration with bacteriophage ΦC31 integrase.

Hillman RT, Calos MP.

Cold Spring Harb Protoc. 2012 May 1;2012(5). pii: pdb.prot069211. doi: 10.1101/pdb.prot069211.

PMID:
22550292
15.

Long-term expression of human coagulation factor VIII in a tolerant mouse model using the φC31 integrase system.

Chavez CL, Keravala A, Chu JN, Farruggio AP, Cuéllar VE, Voorberg J, Calos MP.

Hum Gene Ther. 2012 Apr;23(4):390-8. doi: 10.1089/hum.2011.110. Epub 2012 Jan 26.

16.

Site-specific recombinase strategy to create induced pluripotent stem cells efficiently with plasmid DNA.

Karow M, Chavez CL, Farruggio AP, Geisinger JM, Keravala A, Jung WE, Lan F, Wu JC, Chen-Tsai Y, Calos MP.

Stem Cells. 2011 Nov;29(11):1696-704. doi: 10.1002/stem.730.

17.

Therapeutic applications of the ΦC31 integrase system.

Chavez CL, Calos MP.

Curr Gene Ther. 2011 Oct;11(5):375-81. Review.

PMID:
21888619
18.

The therapeutic potential of ΦC31 integrase as a gene therapy system.

Karow M, Calos MP.

Expert Opin Biol Ther. 2011 Oct;11(10):1287-96. doi: 10.1517/14712598.2011.601293. Epub 2011 Jul 8. Review.

PMID:
21736536
19.

Long-term phenotypic correction in factor IX knockout mice by using ΦC31 integrase-mediated gene therapy.

Keravala A, Chavez CL, Hu G, Woodard LE, Monahan PE, Calos MP.

Gene Ther. 2011 Aug;18(8):842-8. doi: 10.1038/gt.2011.31. Epub 2011 Mar 17.

20.

Site-specific integration of transgene targeting an endogenous lox-like site in early mouse embryos.

Ito M, Yamanouchi K, Naito K, Calos MP, Tojo H.

J Appl Genet. 2011 Feb;52(1):89-94. doi: 10.1007/s13353-010-0011-3. Epub 2010 Nov 26.

PMID:
21110150
21.

Impact of hydrodynamic injection and phiC31 integrase on tumor latency in a mouse model of MYC-induced hepatocellular carcinoma.

Woodard LE, Keravala A, Jung WE, Wapinski OL, Yang Q, Felsher DW, Calos MP.

PLoS One. 2010 Jun 29;5(6):e11367. doi: 10.1371/journal.pone.0011367.

22.

Kinetics and longevity of ΦC31 integrase in mouse liver and cultured cells.

Chavez CL, Keravala A, Woodard LE, Hillman RT, Stowe TR, Chu JN, Calos MP.

Hum Gene Ther. 2010 Oct;21(10):1287-97. doi: 10.1089/hum.2010.049.

23.

Effect of nuclear localization and hydrodynamic delivery-induced cell division on phiC31 integrase activity.

Woodard LE, Hillman RT, Keravala A, Lee S, Calos MP.

Gene Ther. 2010 Feb;17(2):217-26. doi: 10.1038/gt.2009.136. Epub 2009 Oct 22.

24.

Mutational derivatives of PhiC31 integrase with increased efficiency and specificity.

Keravala A, Lee S, Thyagarajan B, Olivares EC, Gabrovsky VE, Woodard LE, Calos MP.

Mol Ther. 2009 Jan;17(1):112-20. doi: 10.1038/mt.2008.241. Epub 2008 Nov 11.

25.

Factoring nonviral gene therapy into a cure for hemophilia A.

Gabrovsky V, Calos MP.

Curr Opin Mol Ther. 2008 Oct;10(5):464-70. Review.

PMID:
18830922
26.

Long-term transgene expression in mouse neural progenitor cells modified with phiC31 integrase.

Keravala A, Ormerod BK, Palmer TD, Calos MP.

J Neurosci Methods. 2008 Aug 30;173(2):299-305. doi: 10.1016/j.jneumeth.2008.06.005. Epub 2008 Jun 17.

27.

Site-specific chromosomal integration mediated by phiC31 integrase.

Keravala A, Calos MP.

Methods Mol Biol. 2008;435:165-73. doi: 10.1007/978-1-59745-232-8_12.

PMID:
18370075
28.
29.

The phiC31 integrase system for gene therapy.

Calos MP.

Curr Gene Ther. 2006 Dec;6(6):633-45. Review.

PMID:
17168696
30.

Long-term increase in mVEGF164 in mouse hindlimb muscle mediated by phage phiC31 integrase after nonviral DNA delivery.

Portlock JL, Keravala A, Bertoni C, Lee S, Rando TA, Calos MP.

Hum Gene Ther. 2006 Aug;17(8):871-6.

PMID:
16942446
31.

Gene transfer to rabbit retina with electron avalanche transfection.

Chalberg TW, Vankov A, Molnar FE, Butterwick AF, Huie P, Calos MP, Palanker DV.

Invest Ophthalmol Vis Sci. 2006 Sep;47(9):4083-90.

PMID:
16936128
32.

PhiC31 integrase mediates integration in cultured synovial cells and enhances gene expression in rabbit joints.

Keravala A, Portlock JL, Nash JA, Vitrant DG, Robbins PD, Calos MP.

J Gene Med. 2006 Aug;8(8):1008-17.

PMID:
16779871
33.

A diversity of serine phage integrases mediate site-specific recombination in mammalian cells.

Keravala A, Groth AC, Jarrahian S, Thyagarajan B, Hoyt JJ, Kirby PJ, Calos MP.

Mol Genet Genomics. 2006 Aug;276(2):135-46. Epub 2006 May 13.

PMID:
16699779
34.

Phage phiC31 integrase-mediated genomic integration of the common cytokine receptor gamma chain in human T-cell lines.

Ishikawa Y, Tanaka N, Murakami K, Uchiyama T, Kumaki S, Tsuchiya S, Kugoh H, Oshimura M, Calos MP, Sugamura K.

J Gene Med. 2006 May;8(5):646-53.

PMID:
16508910
35.

Integration specificity of phage phiC31 integrase in the human genome.

Chalberg TW, Portlock JL, Olivares EC, Thyagarajan B, Kirby PJ, Hillman RT, Hoelters J, Calos MP.

J Mol Biol. 2006 Mar 17;357(1):28-48. Epub 2005 Dec 22.

PMID:
16414067
36.

Enhancement of plasmid-mediated gene therapy for muscular dystrophy by directed plasmid integration.

Bertoni C, Jarrahian S, Wheeler TM, Li Y, Olivares EC, Calos MP, Rando TA.

Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):419-24. Epub 2005 Dec 30.

37.
38.

Site-specific integration for high-level protein production in mammalian cells.

Thyagarajan B, Calos MP.

Methods Mol Biol. 2005;308:99-106. No abstract available.

PMID:
16082029
39.

phiC31 integrase confers genomic integration and long-term transgene expression in rat retina.

Chalberg TW, Genise HL, Vollrath D, Calos MP.

Invest Ophthalmol Vis Sci. 2005 Jun;46(6):2140-6.

PMID:
15914635
40.

In vivo correction of murine hereditary tyrosinemia type I by phiC31 integrase-mediated gene delivery.

Held PK, Olivares EC, Aguilar CP, Finegold M, Calos MP, Grompe M.

Mol Ther. 2005 Mar;11(3):399-408.

41.

Nucleofection of muscle-derived stem cells and myoblasts with phiC31 integrase: stable expression of a full-length-dystrophin fusion gene by human myoblasts.

Quenneville SP, Chapdelaine P, Rousseau J, Beaulieu J, Caron NJ, Skuk D, Mills P, Olivares EC, Calos MP, Tremblay JP.

Mol Ther. 2004 Oct;10(4):679-87.

42.

Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells.

Dorigo O, Gil JS, Gallaher SD, Tan BT, Castro MG, Lowenstein PR, Calos MP, Berk AJ.

J Virol. 2004 Jun;78(12):6556-66.

43.

Construction of transgenic Drosophila by using the site-specific integrase from phage phiC31.

Groth AC, Fish M, Nusse R, Calos MP.

Genetics. 2004 Apr;166(4):1775-82.

44.

Phage integrases: biology and applications.

Groth AC, Calos MP.

J Mol Biol. 2004 Jan 16;335(3):667-78. Review.

PMID:
14687564
45.

Phage integrases for the construction and manipulation of transgenic mammals.

Hollis RP, Stoll SM, Sclimenti CR, Lin J, Chen-Tsai Y, Calos MP.

Reprod Biol Endocrinol. 2003 Nov 7;1:79.

46.

Site-specific genomic strategies for gene therapy.

Portlock JL, Calos MP.

Curr Opin Mol Ther. 2003 Aug;5(4):376-82. Review.

PMID:
14513680
47.

PhiC31 integrase-mediated nonviral genetic correction of junctional epidermolysis bullosa.

Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Calos MP, Khavari PA.

Hum Gene Ther. 2003 Jun 10;14(9):923-8.

PMID:
12828862
48.

Epstein-Barr virus vectors provide prolonged robust factor IX expression in mice.

Sclimenti CR, Neviaser AS, Baba EJ, Meuse L, Kay MA, Calos MP.

Biotechnol Prog. 2003 Jan-Feb;19(1):144-51.

PMID:
12573017
49.

Site-specific genomic integration produces therapeutic Factor IX levels in mice.

Olivares EC, Hollis RP, Chalberg TW, Meuse L, Kay MA, Calos MP.

Nat Biotechnol. 2002 Nov;20(11):1124-8. Epub 2002 Oct 15.

PMID:
12379870
50.

Stable nonviral genetic correction of inherited human skin disease.

Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Fang M, Calos MP, Khavari PA.

Nat Med. 2002 Oct;8(10):1166-70. Epub 2002 Sep 16. Erratum in: Nat Med. 2003 Feb;9(2):237.

PMID:
12244305

Supplemental Content

Loading ...
Support Center